CRISPR Therapeutics AG
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M | $1.17B | $943.8M | $456.6M |
| Accounts Receivable | $0 | $25.0M | $200.0M | $0 | $305.0K | $144.0K | $99.0K | $88.0K |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $987.5M | $466.4M |
| Property, Plant & Equipment | $115.9M | $134.1M | $151.9M | $163.6M | $137.6M | $42.2M | $31.3M | $18.5M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.0M |
| Liabilities | ||||||||
| Accounts Payable | $11.1M | $14.7M | $38.1M | $27.4M | $14.8M | $9.1M | $5.9M | $5.1M |
| Total Current Liabilities | $149.1M | $87.8M | $108.8M | $121.1M | $119.9M | $94.3M | $57.1M | $27.7M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M | $163.7M | $127.3M | $96.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.95B | $-1.37B | $-999.7M | $-846.1M | $-195.9M | $-573.6M | $-224.7M | $-291.6M |
| Total Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.4M | $392.2M |